RU2367468C2 - БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ - Google Patents

БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ Download PDF

Info

Publication number
RU2367468C2
RU2367468C2 RU2006121466/15A RU2006121466A RU2367468C2 RU 2367468 C2 RU2367468 C2 RU 2367468C2 RU 2006121466/15 A RU2006121466/15 A RU 2006121466/15A RU 2006121466 A RU2006121466 A RU 2006121466A RU 2367468 C2 RU2367468 C2 RU 2367468C2
Authority
RU
Russia
Prior art keywords
bcl
peptide
protein
hla
peptide fragment
Prior art date
Application number
RU2006121466/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2006121466A (ru
Inventor
Эйвинд Пер Тор СТРАТЕН (DK)
Эйвинд Пер Тор СТРАТЕН
Мадс Хальд АНДЕРСЕН (DK)
Мадс Хальд АНДЕРСЕН
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of RU2006121466A publication Critical patent/RU2006121466A/ru
Application granted granted Critical
Publication of RU2367468C2 publication Critical patent/RU2367468C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2006121466/15A 2003-11-19 2004-11-18 БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ RU2367468C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US52311903P 2003-11-19 2003-11-19
DKPA200301716 2003-11-19
US60/523,119 2003-11-19
DKPA200301716 2003-11-19

Publications (2)

Publication Number Publication Date
RU2006121466A RU2006121466A (ru) 2007-12-27
RU2367468C2 true RU2367468C2 (ru) 2009-09-20

Family

ID=39149116

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006121466/15A RU2367468C2 (ru) 2003-11-19 2004-11-18 БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ

Country Status (17)

Country Link
US (1) US7842294B2 (https=)
EP (2) EP1691824B1 (https=)
JP (2) JP4926714B2 (https=)
KR (2) KR101284237B1 (https=)
CN (1) CN1921878B (https=)
AT (1) ATE424842T1 (https=)
AU (1) AU2004290866B2 (https=)
CA (1) CA2546794C (https=)
DE (1) DE602004019965D1 (https=)
DK (2) DK2087904T3 (https=)
ES (2) ES2323588T3 (https=)
MX (1) MXPA06005738A (https=)
PL (2) PL2087904T3 (https=)
PT (1) PT1691824E (https=)
RU (1) RU2367468C2 (https=)
WO (1) WO2005049073A2 (https=)
ZA (1) ZA200604866B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2570560C2 (ru) * 2010-03-11 2015-12-10 Онкотерапи Сайенс, Инк. Пептиды hjurp и содержащие их вакцины
RU2671897C2 (ru) * 2013-03-01 2018-11-07 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке
RU2785794C2 (ru) * 2021-05-17 2022-12-13 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Пептидные соединения для индукции апоптоза в опухолевой клетке

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
ES2633389T3 (es) * 2003-01-30 2017-09-21 Survac Aps Péptidos derivados de survivina y uso de los mismos
US20130052215A9 (en) 2003-09-26 2013-02-28 Eckhard Podack Tumor vaccine
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
AU2005295194A1 (en) * 2004-10-19 2006-04-27 Massachusetts Institute Of Technology Virus scaffold for self-assembled, flexible and light lithium battery
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
AU2011203535B2 (en) * 2005-02-04 2012-10-11 Survac Aps Survivin peptide vaccine
JP5114418B2 (ja) * 2005-09-09 2013-01-09 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ 細胞死を抑制する又は細胞増殖を高めるための方法及び組成物
WO2008116468A2 (en) 2007-03-26 2008-10-02 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP3620465B1 (en) 2007-07-03 2025-02-19 Dako Denmark A/S Improved methods for generation, labeling and use of mhc multimers
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
EP2254592B1 (en) * 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
SG10201803982TA (en) 2008-05-16 2018-07-30 Taiga Biotechnologies Inc Antibodies and processes for preparing the same
EP2313516A4 (en) * 2008-07-16 2012-04-04 Burnham Inst Medical Research COMPOSITIONS AND METHODS FOR MODULATING THE NOD LIKE RECEPTOR ACTIVITY AND THEIR USE
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
DK3339321T3 (da) 2008-08-28 2021-06-21 Taiga Biotechnologies Inc Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037397A1 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cmv immune monitoring
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
WO2011066048A1 (en) * 2009-10-22 2011-06-03 Thomas Jefferson University Cell-based anti-cancer compositions and methods of making and using the same
CA2809362C (en) * 2010-08-24 2020-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
CA3183703A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
US9789135B2 (en) * 2012-07-20 2017-10-17 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
EP2961419A4 (en) * 2013-02-26 2016-12-21 Rongfu Wang PHF20 AND JMJD3 COMPOSITIONS AND METHOD FOR USE IN CANCER IMMUNOTHERAPY
US9704181B2 (en) * 2014-05-06 2017-07-11 International Business Machines Corporation Real-time social group based bidding system
EP3548425B1 (en) 2016-12-02 2023-03-29 Taiga Biotechnologies, Inc. Nanoparticle formulations
WO2018138257A1 (en) * 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SI3573647T1 (sl) 2017-01-27 2023-07-31 Immatics Biotechnologies Gmbh Peptidi in kombinacija peptidov za uporabo v imunoterapiji proti raku jajčnikov in drugim oblikam raka
US10738100B2 (en) 2017-01-27 2020-08-11 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
JP7642530B2 (ja) 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
CN113874033A (zh) 2019-04-08 2021-12-31 泰加生物工艺学公司 用于冷冻保存免疫细胞的组合物和方法
EP3969041A4 (en) 2019-05-14 2023-05-10 Taiga Biotechnologies, Inc. COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION
CN113355432A (zh) * 2021-05-12 2021-09-07 甘肃农业大学 Bmf作为细胞凋亡标志物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856171A (en) * 1993-08-26 1999-01-05 Washington University Cell death regulators

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5342774A (en) 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
JP3608788B2 (ja) 1992-08-31 2005-01-12 ルドヴィグ・インスティテュート・フォー・キャンサー・リサーチ Ｍａｇｅ−３遺伝子から誘導されてｈｌａ−ａ１により提示される単離されたノナペプチドおよびそれらの用途
US5470955A (en) * 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
US5646008A (en) * 1993-06-22 1997-07-08 The Regent Of The University Of Michigan Vertebrate apoptosis gene: compositions and methods
GB9320597D0 (en) 1993-10-06 1993-11-24 Proteus Molecular Design Improvements in and realting to vaccines
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US5789201A (en) * 1996-02-23 1998-08-04 Cocensys, Inc. Genes coding for bcl-y a bcl-2 homologue
ATE414149T1 (de) 1996-11-20 2008-11-15 Univ Yale Survivin, ein protein das zelluläre apoptosis hemmt, und dessen modulation
WO1998058541A1 (en) * 1997-06-24 1998-12-30 Dana-Farber Cancer Institute, Inc. Modulation of apoptosis
AU3471200A (en) * 1999-11-16 2001-05-30 Dartmouth College Mcl-1 gene regulatory elements and a pro-apoptotic mcl-1 variant
JP2003516744A (ja) * 1999-12-14 2003-05-20 ザ バーナム インスティチュート Ｂｃｌ−ｇポリペプチド、それをコードする核酸および使用方法
AU2001271426A1 (en) * 2000-07-17 2002-01-30 Washington University Modulation of apoptosis
AU2002257647A1 (en) * 2001-03-09 2002-09-24 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
EP1618130B1 (en) 2003-04-11 2013-03-27 Survac ApS Therapeutic cancer vaccine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856171A (en) * 1993-08-26 1999-01-05 Washington University Cell death regulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AKATSUKA Y. et al., Identification a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens, J. Exp. Med., 2003 June 2, v.197, №11, pp.1489 - 1500. SCHMIDT S.M. et al., Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxcic Т cells, Immunobiology, 2003 15 July, v.102, №2, pp.571-576. *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2570560C2 (ru) * 2010-03-11 2015-12-10 Онкотерапи Сайенс, Инк. Пептиды hjurp и содержащие их вакцины
US9403890B2 (en) 2010-03-11 2016-08-02 Oncotherapy Science, Inc. HJURP peptides and vaccines including the same
US9896492B2 (en) 2010-03-11 2018-02-20 Oncotherapy Science, Inc. HJURP peptides and vaccines including the same
RU2671897C2 (ru) * 2013-03-01 2018-11-07 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Способы получения из опухоли обогащенных популяций реактивных в отношении опухоли т-клеток
WO2022245249A1 (ru) * 2021-05-17 2022-11-24 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) Пептидные соединения для индукции апоптоза в опухолевой клетке
RU2785794C2 (ru) * 2021-05-17 2022-12-13 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Пептидные соединения для индукции апоптоза в опухолевой клетке
RU2796104C1 (ru) * 2022-09-16 2023-05-17 федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет) (ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава России (Се Применение пептидного соединения для индукции апоптоза в опухолевой клетке

Also Published As

Publication number Publication date
KR20130026527A (ko) 2013-03-13
US20080050396A1 (en) 2008-02-28
ZA200604866B (en) 2008-05-28
HK1101131A1 (en) 2007-10-12
JP2011246496A (ja) 2011-12-08
DK1691824T3 (da) 2009-07-06
EP2087904A1 (en) 2009-08-12
PL1691824T3 (pl) 2009-08-31
US7842294B2 (en) 2010-11-30
DE602004019965D1 (de) 2009-04-23
ES2436429T3 (es) 2014-01-02
JP5502823B2 (ja) 2014-05-28
PL2087904T3 (pl) 2014-01-31
RU2006121466A (ru) 2007-12-27
DK2087904T3 (da) 2013-12-02
CA2546794A1 (en) 2005-06-02
EP1691824A2 (en) 2006-08-23
EP1691824B1 (en) 2009-03-11
JP4926714B2 (ja) 2012-05-09
AU2004290866B2 (en) 2010-09-02
WO2005049073A2 (en) 2005-06-02
AU2004290866A1 (en) 2005-06-02
CN1921878A (zh) 2007-02-28
KR101284237B1 (ko) 2013-07-09
CN1921878B (zh) 2012-04-25
WO2005049073A3 (en) 2006-01-05
MXPA06005738A (es) 2006-12-14
ATE424842T1 (de) 2009-03-15
PT1691824E (pt) 2009-05-28
CA2546794C (en) 2013-09-17
KR20060132622A (ko) 2006-12-21
EP2087904B1 (en) 2013-08-28
KR101216655B1 (ko) 2013-01-02
ES2323588T3 (es) 2009-07-21
JP2007511547A (ja) 2007-05-10

Similar Documents

Publication Publication Date Title
RU2367468C2 (ru) БЕЛКИ, ОТНОСЯЩИЕСЯ К СЕМЕЙСТВУ Всl-2, И ИХ ФРАГМЕНТЫ И ИХ ПРИМЕНЕНИЕ У ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
US8933038B2 (en) Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
RU2396088C2 (ru) Вакцина на основе пептидов сурвивина
US20090148400A1 (en) Composition of tumour-associated peptides and related anti-cancer vaccine
US20160008448A1 (en) Rhoc-based immunotherapy
JP4365405B2 (ja) Ｍｈｃ分子と結合する腫瘍関連ペプチド
HK1101131B (en) Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
HK1125968B (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same